aTyr Pharma Nabs $23M

San Diego-based aTyr Pharma, a developer of biotherapeutics aimed at the blood, immune, and metabolism disorder areas, announced today that it has raised $23M in a Series C equity financing round. The round was led by Domain Associates, and also included prior investors Alta Partners, Cardinal Partners, and Polar Ventures. According to aTyr, the new funding will go towards accelerating its preclinical pipeline and to advance products into clinical trials. James C. Blair of Domain Associates joins the company's board as part of the funding. aTyr is headed by Jeff Watkins. More information »